ArticleFrontiers in bioengineering and biotechnology2025
Resonant acoustic mixing-assisted fabrication and evaluation of FDM-printed PLA/β-TCP scaffolds for bone tissue engineering.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Composite scaffolds combining polylactic acid (PLA) with β-tricalcium phosphate (β-TCP) offer potential for bone tissue engineering (BTE) by integrating mechanical support with bioactivity. However, the optimal ratio balancing biological performance, structural integrity, and manufacturing feasibility remains unclear. Methods: PLA/β-TCP composites containing 0%, 10%, 20%, and 30% β-TCP were prepared using solvent-free resonant acoustic mixing (RAM), extruded into filaments, and printed by fused deposition modeling (FDM). Scaffolds were evaluated for mechanical properties, printability, and Results: All β-TCP-containing scaffolds enhanced cell adhesion, proliferation, and osteogenesis compared with pure PLA. The 80:20 PLA/β-TCP scaffold showed optimal balance of bioactivity, compressive strength, and printing quality. Excessive β-TCP (>20%) reduced mechanical strength and caused printing defects. Conclusion: The 80:20 PLA/β-TCP composition offers an optimal balance of biological activity, mechanical performance, and manufacturing scalability, supporting its potential as a cost-effective scaffold for clinical BTE applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.